3837s1 06 Tally

Information about 3837s1 06 Tally

Published on January 9, 2008

Author: Modest

Source: authorstream.com

Content

Challenges in Antibacterial Drug Development :  Challenges in Antibacterial Drug Development Francis P. Tally M.D. Cubist Pharmaceuticals, Inc. Francis P. Tally M.D. Background:  Francis P. Tally M.D. Background Tufts/New England Medical Center 1975-1986 Infectious Disease, Senior Physician Principal Investigator – 7 New Antimicrobials Lederle/Wyeth 1987-1995 Executive Director, Infectious Disease Research Registered Zosyn (piperacillin sodium & tazobacam sodium) – 1993 Involved with discovery of tigecycline Cubist Pharmaceuticals, Inc. 1995 – present Currently working to develop daptomycin Challenges in Antibacterial Drug Development Characteristics of the Drug:  Challenges in Antibacterial Drug Development Characteristics of the Drug Broad Spectrum vs. Narrow Spectrum Oral and/or IV Modification of Existing Class vs. Novel Class Challenges in Antibacterial Drug Development :  Challenges in Antibacterial Drug Development Challenges in Antibacterial Drug Development Characteristics to Justify Development:  Challenges in Antibacterial Drug Development Characteristics to Justify Development Microbiological Superiority Inhibit resistant organisms Pharmacological Advantage Frequency of dosing Ease of administration Safety Advantage Challenges in Antibacterial Drug Development Classification of New Antibacterial Drugs:  Challenges in Antibacterial Drug Development Classification of New Antibacterial Drugs Broad Spectrum – Existing Classes Carbapenem – oral; qd Penicillin / ß-lactamase inhibitor Cephalosporin – MRSA activity Narrow Spectrum – Gram+ Susceptible and Resistant Organisms New Drug Class – Covers Resistant Organisms Challenges in Antibacterial Clinical Protocol Development:  Challenges in Antibacterial Clinical Protocol Development Spectrum and Drug Distribution Defines the Clinical Indications to Be Studied PK/PD Guide to Dose Selection Preclinical Safety Profile Influences Patient Selection Clinical Trial Design Superiority Noninferiority Challenges in Antibacterial Drug Development Trial Design:  Challenges in Antibacterial Drug Development Trial Design Clinical Indications and Organisms Encountered Monomicrobial – S. aureus – cSST Mixed infection – intra-abdominal Potential Pathogens Dictate Selection of Comparative Agents Narrow – UTI, SST Divergent – CAP, nosocomial pneumonia, intraabdominal infection Bacterial Causes of Pneumonia:  Bacterial Causes of Pneumonia Challenges in Antibacterial Drug Development Trial Design:  Challenges in Antibacterial Drug Development Trial Design Type of Controlled Trial to Prove Noninferiority Blinded double or investigator open label – microbiology endpoint Sample Size “delta” 95% Confidence Interval projected efficacy rate End Points – Clinical vs. Microbiological Challenges in Antibacterial Drug Development Challenges of Selecting Delta for Clinical Trial:  Challenges in Antibacterial Drug Development Challenges of Selecting Delta for Clinical Trial Is Drug Therapy Better Than Placebo – Superiority Placebo controlled requires monitoring board Seriousness of the Infection – Affects Delta Mild: Impetigo, UTI, gonorrhea Moderate: Bacteremia/Nosocomial pneumonia Severe (rare): Endocarditis/Meningitis Is Drug Equal to Standard of Care “Biocreep” in mild infections Serious infection – select best therapy Challenges in Antibacterial Drug Development “Biocreep”:  Challenges in Antibacterial Drug Development “Biocreep” Historically, drugs with lower efficacy rates than standard of care can be approved with wider deltas Theoretically, one could sequentially compare and approve slightly inferior products relative to an approved standard of care “Biocreep” – over time a product could be approved as noninferior that would not be better than placebo Challenges in Antibacterial Drug Development Delta – Related to Efficacy Rates in 1992:  Challenges in Antibacterial Drug Development Delta – Related to Efficacy Rates in 1992 Challenges in Antibacterial Drug Development Impact of Small Delta:  Challenges in Antibacterial Drug Development Impact of Small Delta Number of Patients to Be Enrolled is Greatly Increased Time to Complete Enrollment Measured in Years Enrollment Outside U.S. Patient population differs Control for study variables Cost of Drug Development Big Pharma Biotech / Specialty Pharma Challenges in Antibacterial Drug Development Opinion:  Challenges in Antibacterial Drug Development Opinion “Biocreep” Should Be Stopped Selection of comparative agent in collaboration with academic societies’ cited guidelines Infectious Disease Society of America American College of Pediatrics Society for Critical Care Medicine American College of Surgeons Challenges in Antibacterial Drug Development Opinion:  Challenges in Antibacterial Drug Development Opinion Oral Drugs for Common Community Diseases Skin and skin structure Sinusitis Otitis media Bronchitis Urinary tract infection Gonorrhea 10% Delta Appropriate Challenges in Antibacterial Drug Development Opinion:  Challenges in Antibacterial Drug Development Opinion IV Drug for Serious Infections Delta Should be Based on Clinical Knowledge of the Infection Challenges in Antibacterial Drug Development Problems With IV Only Drugs:  Challenges in Antibacterial Drug Development Problems With IV Only Drugs Serious Infections – Limited Subjects for Enrollment – cSST, Pneumonia, Intraabdominal Selection of Comparative Agent (Stop Biocreep) Inpatient Hospital Requirement vs. Home IV Therapy Criteria for oral switch – small delta magnifies the challenges to perform adequate studies Challenges in Antibacterial Drug Development Opinion – Paradox of Higher Mortality Infections:  Challenges in Antibacterial Drug Development Opinion – Paradox of Higher Mortality Infections Widest Delta in Severe Disease such as Meningitis and Bacterial Endocarditis – because sterilization of blood or CSF are hard end points Challenges in Antibacterial Drug Development Overall Conclusions on Delta:  Challenges in Antibacterial Drug Development Overall Conclusions on Delta Community-acquired common infections are where the most “Biocreep” has occurred. Therefore a small delta is appropriate and the best comparative agent should be selected. Intravenous therapy for serious infections are the main problem in clinical development where physicians will select the best therapy. The delta should be based on statistical and clinical considerations and comparative therapy should represent the standard of care. Challenges in Antibacterial Drug Development Overall Conclusions on Delta:  Challenges in Antibacterial Drug Development Overall Conclusions on Delta Severe infections (e.g. meningitis and bacterial endocarditis) require the widest deltas because microbiology end points are firm and incidence of infection is low.

Related presentations


Other presentations created by Modest

green building
24. 01. 2008
0 views

green building

hippo oath
29. 01. 2008
0 views

hippo oath

pmi integration notes
09. 01. 2008
0 views

pmi integration notes

NLO Lect1
11. 01. 2008
0 views

NLO Lect1

Lecture 23 Cellular Slime Molds
12. 01. 2008
0 views

Lecture 23 Cellular Slime Molds

teaching slideshow
14. 01. 2008
0 views

teaching slideshow

sound
15. 01. 2008
0 views

sound

Blazing the Trail
17. 01. 2008
0 views

Blazing the Trail

shabanov PHD
17. 01. 2008
0 views

shabanov PHD

MRCME Chronic Diarrhea
18. 01. 2008
0 views

MRCME Chronic Diarrhea

105 obrien p
17. 01. 2008
0 views

105 obrien p

1021 ESF 1830
04. 02. 2008
0 views

1021 ESF 1830

ubc poster
11. 02. 2008
0 views

ubc poster

shat Vietnam
12. 02. 2008
0 views

shat Vietnam

mysql
30. 01. 2008
0 views

mysql

vienna
07. 02. 2008
0 views

vienna

SBI PI05 harvey
07. 02. 2008
0 views

SBI PI05 harvey

Meditation Anjali Dhurandhar
07. 02. 2008
0 views

Meditation Anjali Dhurandhar

BouncingBalls
13. 02. 2008
0 views

BouncingBalls

LearningTrackV ASP NET
20. 02. 2008
0 views

LearningTrackV ASP NET

ozone hole w notes
20. 02. 2008
0 views

ozone hole w notes

amst03 filmweb
21. 01. 2008
0 views

amst03 filmweb

Presentation Ergonomics
07. 03. 2008
0 views

Presentation Ergonomics

Livy
10. 03. 2008
0 views

Livy

Sunny1
21. 03. 2008
0 views

Sunny1

MCS 12 Satellite Systems
27. 03. 2008
0 views

MCS 12 Satellite Systems

ehrenfreund
25. 01. 2008
0 views

ehrenfreund

2005london2012
14. 04. 2008
0 views

2005london2012

coaches
15. 04. 2008
0 views

coaches

seminaire160604chine def
17. 04. 2008
0 views

seminaire160604chine def

wipo ipr mct 05 2
22. 04. 2008
0 views

wipo ipr mct 05 2

Security0505
24. 04. 2008
0 views

Security0505

VietnamAPEC2006
07. 05. 2008
0 views

VietnamAPEC2006

opening07 en
08. 05. 2008
0 views

opening07 en

DSpace Concept Linking Zhou
02. 05. 2008
0 views

DSpace Concept Linking Zhou

reprolecture
15. 01. 2008
0 views

reprolecture

LDAC 04 Briefing
14. 02. 2008
0 views

LDAC 04 Briefing

Art That Inspires 1
03. 03. 2008
0 views

Art That Inspires 1

CityStates Greece
02. 05. 2008
0 views

CityStates Greece

Language Immersion Summary
10. 01. 2008
0 views

Language Immersion Summary

BCWS oct19th06 partc
24. 03. 2008
0 views

BCWS oct19th06 partc

O3guide
21. 02. 2008
0 views

O3guide

0409588
09. 01. 2008
0 views

0409588

NMGIC Hummingbird Presentation
03. 04. 2008
0 views

NMGIC Hummingbird Presentation

Lec07 LOOKING AT DATA
04. 02. 2008
0 views

Lec07 LOOKING AT DATA

Restart Based CP REVISED
28. 01. 2008
0 views

Restart Based CP REVISED

SpaceOps02 Pre T3 24
16. 01. 2008
0 views

SpaceOps02 Pre T3 24

Transportation In London
07. 02. 2008
0 views

Transportation In London

FrankPagano
08. 01. 2008
0 views

FrankPagano